CAPR vs RARE vs SRPT vs CRSP vs EDIT

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -100. 0% for Editas Medicine, Inc. (EDIT). Analysts rate Capricor Therapeutics, Inc. (CAPR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Capricor Therapeutics, Inc.

(CAPR) delivered a total return of +778. 0%, compared to -90. 1% for Editas Medicine, Inc. (EDIT). Over 10 years, the gap is even starker: CRSP returned +289. 1% versus EDIT's -89. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.

(RARE) is the lower-risk stock at 1. 36β versus Editas Medicine, Inc. 's 2. 45β — meaning EDIT is approximately 79% more volatile than RARE relative to the S&P 500. On balance sheet safety, Capricor Therapeutics, Inc. (CAPR) carries a lower debt/equity ratio of 1% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus -100. 0% for Editas Medicine, Inc. (EDIT). On earnings-per-share growth, the picture is similar: Editas Medicine, Inc. grew EPS 37. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, CAPR leads at 349. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Editas Medicine, Inc.

(EDIT) is the more profitable company, earning 0. 0% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EDIT leads at 0. 0% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RARE: 85.

1% to $48. 36.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Editas Medicine, Inc. (EDIT) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RARE: -59. 4%, EDIT: -89. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CAPR is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; SRPT is a small-cap high-growth stock; CRSP is a small-cap quality compounder stock; EDIT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.